TY - JOUR
T1 - Trends affecting the future of vaccine development and delivery
T2 - The role of demographics, regulatory science, the anti-vaccine movement, and vaccinomics
AU - Poland, Gregory A.
AU - Jacobson, Robert M.
AU - Ovsyannikova, Inna G.
N1 - Funding Information:
Drs. Poland and Jacobson serve as investigators for vaccine clinical studies funded by Wyeth, and an anthrax vaccine trial funded by the CDC. Dr. Poland is the chair of a DMSB for novel experimental vaccines being developed by Merck Research Laboratories. In addition, he has offered consulting advice on vaccine development to GlaxoSmithKline, Novartis, Novavax, Dynavax, CSL Limited and Biotherapies, PowderMed, Avianax, and Emergent Biosolutions. Dr. Jacobson serves on a DSMB funded by Kaiser Permanente concerning HPV vaccine manufactured by Merck Research Laboratories.
Funding Information:
Drs. Poland, Jacobson, and Ovsyannikova are supported by grants AI 33144, AI 48793 and AI 40065 from the National Institutes of Health. We thank the many study volunteers and vaccine research group staff who have made our studies possible.
PY - 2009/5/26
Y1 - 2009/5/26
N2 - Important scientific, cultural, temporal, and secular issues impact the development of, and delivery of vaccines. In this paper we discuss the impact of demographics, regulatory science, the anti-vaccine movement, and finally the impact of the new biology and individualized medicine, which we call vaccinomics, on vaccine development and delivery. A description of the issues and how they have, are, or should be impacting vaccinology is provided, and hopefully will result in increased attention and discussion among vaccinologists. These issues have been under-valued, under-discussed, and in some cases, ignored. We hope that discussion of these issues will result in changes in how we develop, and how we communicate those developments, to the public.
AB - Important scientific, cultural, temporal, and secular issues impact the development of, and delivery of vaccines. In this paper we discuss the impact of demographics, regulatory science, the anti-vaccine movement, and finally the impact of the new biology and individualized medicine, which we call vaccinomics, on vaccine development and delivery. A description of the issues and how they have, are, or should be impacting vaccinology is provided, and hopefully will result in increased attention and discussion among vaccinologists. These issues have been under-valued, under-discussed, and in some cases, ignored. We hope that discussion of these issues will result in changes in how we develop, and how we communicate those developments, to the public.
KW - Anti-vaccine
KW - Gene polymorphisms
KW - Randomized clinical trials
KW - Vaccine
KW - Vaccine future
KW - Vaccinomics
UR - http://www.scopus.com/inward/record.url?scp=67349216217&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=67349216217&partnerID=8YFLogxK
U2 - 10.1016/j.vaccine.2009.01.069
DO - 10.1016/j.vaccine.2009.01.069
M3 - Article
C2 - 19200833
AN - SCOPUS:67349216217
SN - 0264-410X
VL - 27
SP - 3240
EP - 3244
JO - Vaccine
JF - Vaccine
IS - 25-26
ER -